Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Completed Phase 1 Trials for Sunitinib (DB01268)

IndicationStatusPhase
DBCOND0029236 (Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00890747Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyTreatment